CorMedix Inc. filed a current report on Form 8-K on November 16, 2026, furnishing the transcript of its investor conference call held on November 12, 2026, which covered financial results for the quarter ended September 30, 2026, and also disclosed a proposed acquisition of substantially all of the assets of Heron Therapeutics, Inc.
Key Highlights
- Conference call date: CorMedix hosted its investor call and webcast on November 12, 2026, covering results for the quarter ended September 30, 2026.
- Transcript furnished: The call transcript is attached as Exhibit 99.1 and incorporated by reference into the filing.
- Proposed acquisition disclosed: CorMedix disclosed a proposed acquisition of substantially all of the assets of Heron Therapeutics, Inc., referred to in the filing as the "Proposed Acquisition."
- Proxy statement anticipated: According to the filing, Heron Therapeutics intends to file a proxy statement on Schedule 14A with the SEC in connection with the Proposed Acquisition.
- Private placement noted: The filing states that shares of CorMedix common stock to be issued to Heron in the Proposed Acquisition "will be issued in a private placement in reliance on an exemption from the registration requirements of the Securities Act."
- Regulation FD item: The transcript disclosure was made under Item 7.01 Regulation FD Disclosure and is designated as "not filed" for purposes of Section 18 of the Exchange Act.
CorMedix Discloses Heron Therapeutics Asset Acquisition Alongside Q3 2026 Earnings Transcript
CorMedix Inc. (NASDAQ:CRMD), a pharmaceutical company incorporated in Delaware and headquartered in Parsippany, New Jersey, filed the current report to furnish the transcript of its November 12, 2026 earnings conference call covering the quarter ended September 30, 2026. The transcript was attached as Exhibit 99.1 and is incorporated by reference. Per the filing, the Item 7.01 disclosure "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not subject to the liabilities of that section.
Beyond the quarterly earnings discussion, the filing prominently references a proposed transaction in which CorMedix would acquire substantially all of the assets of Heron Therapeutics, Inc. The filing indicates that Heron markets four FDA-approved commercial brands and that the Proposed Acquisition is expected by CorMedix to be accretive to earnings, though those characterizations are described in the filing as forward-looking statements subject to risks and uncertainties under the Private Securities Litigation Reform Act of 1995. The filing also notes that CorMedix's existing commercial product, DefenCath, faces considerations related to a 2027 post-TDAPA Add-on adjustment by CMS, and separately references the FDA review of a supplemental New Drug Application for REZZAYO as part of the company's pipeline context provided during the call.
The filing indicates that CorMedix and Heron "and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Heron's stockholders in connection with the Proposed Acquisition." It further notes that Heron's proxy statement for its 2026 annual meeting of stockholders was filed with the SEC on April 30, 2026, and CorMedix's corresponding proxy was filed on April 29, 2026. The filing is checked as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
What Was Disclosed
CorMedix furnished its Q3 2026 earnings call transcript as an exhibit to a current report and simultaneously disclosed the existence of a proposed acquisition of substantially all of Heron Therapeutics, Inc.'s assets, along with related solicitation and forward-looking statement disclosures required under SEC rules.




Please wait processing your request...